Results 61 to 70 of about 9,804 (228)

Charakterisierung des Lipidbindungsverhaltens und der Proteinfaltung von HCV NS5A unter Einfluss des NS5A-Inhibitors Daclatasvir [PDF]

, 2021
Mit 71 Millionen chronisch erkrankten Patienten im Jahr 2015 stellt die chronische Hepatitis C-Virusinfektion eine wichtige Ursache für Zirrhose, Leberdekompensation und Leberkrebs dar. Eine grundlegende Eigenschaft des Hepatitis C-Virus (HCV) ist die Biogenese modifizierter intrazellulärer Membranen.
openaire   +2 more sources

Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors [PDF]

ACS Medicinal Chemistry Letters, 2013
The discovery of potent thienoimidazole-based HCV NS5A inhibitors is herein reported. A novel method to access the thienoimidazole [5,5]-bicyclic system is disclosed. This method gave access to a common key intermediate (6) that was engaged in Suzuki or Sonogashira reactions with coupling partners bearing different linkers.
Simon, Giroux, Jinwang, Xu, T Jagadeeswar, Reddy, Mark, Morris, Kevin M, Cottrell, Caroline, Cadilhac, James A, Henderson, Oliver, Nicolas, Darius, Bilimoria, Francois, Denis, Nagraj, Mani, Nigel, Ewing, Rebecca, Shawgo, Lucille, L'Heureux, Subajini, Selliah, Laval, Chan, Nathalie, Chauret, Francoise, Berlioz-Seux, Mark N, Namchuk, Anne-Laure, Grillot, Youssef L, Bennani, Sanjoy K, Das, John P, Maxwell   +22 more
openaire   +2 more sources

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Virology Journal, 2017
Background In study TMC647055HPC2001, a 3-direct-acting-antiviral (DAA) regimen combining NS3/4A protease inhibitor simeprevir (SMV), non-nucleoside NS5B inhibitor TMC647055/ritonavir (RTV) and NS5A inhibitor JNJ-56914845 resulted in high sustained ...
Leen Vijgen, Kim Thys, An Vandebosch, Pieter Van Remoortere, René Verloes, Sandra De Meyer   +5 more
doaj   +1 more source

Current trends in the treatment of hepatitis C [PDF]

, 2016
Viral hepatitis, an inflammatory liver disease, is caused by various genotypes of hepatitis C viruses (HCV). Hepatitis C slowly sprouts into fibrosis, which progresses to cirrhosis.
Akhtar, Bushra, Akhtar, Muhammad Furqan, Muhammad, Syed Taqi, Mushtaq, Muhammed Fahd, Peerzada, Sohaib, Saleem, Ammara, Saleem, Muhammad, Sharif, Ali   +7 more
core   +1 more source

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug‐Metabolizing Enzymes

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug with potent pan‐genotypic inhibitory activity against hepatitis C virus. In vitro studies assessing the inhibition or induction potential of bemnifosbuvir on the CYP450 and UGT1A1 enzymes demonstrated that bemnifosbuvir is a weak inducer and a reversible and time‐dependent inhibitor of
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Steven Good, Arantxa Horga, Nancy Agrawal, Janet Hammond   +10 more
wiley   +1 more source

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control

Health Science Reports, 2023
Background and Aim Management of genotype 4 hepatitis C virus (HCV) has shifted to interferon‐free regimens with a high sustained virological response (SVR‐12), especially with NS5B/NS5A inhibitor combinations such as sofosbuvir and ledipasvir (Sof‐Led).
Hala Joharji, Delal Alkortas, Aziza Ajlan, Mohamed Ahmed, Hamad Al‐Ashgar, Mohammed Al‐Quaiz, Dieter Broering, Mohammed Al‐Sebayel, Hussien Elsiesy, Faisal A. Alkhail, Waleed K. Al‐Hamoudi, Edward De Vol, Epi Amirah Almuhayshir, Ahmed Al‐Jedai   +13 more
doaj   +1 more source

IP-10 Interferes With the Antiviral Response of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection

Frontiers in Public Health, 2022
BackgroundIncreased interferon (IFN)-gamma inducible protein-10 (IP-10) level has been shown to be associated with sustained virologic responses (SVRs) to pegylated interferon-alpha 2a/ribavirin-based therapy in patients with chronic hepatitis C (CHC ...
Yadong Wang, Yangyang Hu, Xing Zhang, Yue Luo, Luyuan Ma, Jingjing Lu, Qianfei Liang, Chengjun Xu, Caiyan Zhao, Calvin Q. Pan, Calvin Q. Pan   +10 more
doaj   +1 more source

Plant-derived antivirals against hepatitis c virus infection [PDF]

, 2018
Hepatitis C virus (HCV) infection is a worldwide public health burden and it is estimated that 185 million people are or have previously been infected worldwide.
Harris, M, Jardim, ACG, Rahal, P, Shimizu, JF   +3 more
core   +1 more source

Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH)

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral Hepatitis (ESGVH) convened to examine the role of vaccination as the cornerstone of hepatitis prevention ...
Oana Săndulescu, Gülşen Özkaya Şahin, Susanne Gjeruldsen Dudman, Zeinab Nabil Ahmed Said, Mario U. Mondelli, on behalf of ESCMID Study Group for Viral Hepatitis (ESGVH)   +5 more
wiley   +1 more source